Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.

Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec 01;: Authors: Kostaras D, Karampli E, Athanasakis K Abstract INTRODUCTION: During the last years, a significant number economic evaluations of HPV vaccination has been published. Given that cost-effectiveness constitutes an essential part of decision-making with regards to the reimbursement of a health technology, the purpose of this study is to provide a supportive tool to decision-makers regarding the economic efficiency of the introduction of HPV vaccination to national immunization programs. Areas covered: The PubMed database was searched in order to identify cost-effectiveness studies for HPV vaccination. A total of 42 articles were finally retrieved. All retrieved cost effectiveness ratios (ICERs) were converted in the same currency unit (I$) and then inflated to the same year (2015) in order to facilitate cross-country comparisons. RESULTS: Overall, vaccination against HPV 6,11,16,18 types appears to have a cost effectiveness ratio (ICER) with mean value of I$25132/QALY, whereas the mean ICER of vaccination against oncogenic HPV 16,18 types is estimated at I$38,253/QALY. Expert commentary: HPV vaccination would be a cost-effective intervention in the setting of high income countries and could reduce the incidence of HPV related diseases. PMID: 30501434 [PubMed...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research